This is a small study that suggests the treatment is safe, said Dr. Kirk Garrett, clinical director of interventional cardiovascular research at Lenox Hill Hospital in New York City. "The approach is different in that most other groups zero in on one gene or cell type, and try to make it do the work," he said, while the new treatment involves both stem cells and immune cells that are primed to do the job.
Because this study was presented at a medical meeting, the data and conclusions should be viewed as preliminary until published in a peer-reviewed journal.
More information
Learn more about heart failure and how it is treated at the U.S. National Heart, Lung, and Blood Institute.
Copyright © 2012 HealthDay. All rights reserved.
Reader Comments Read all comments (1)